APA (7th ed.) Citation

Chueh, C., Tsai, Y., Chen, Z., Shiu, M., Wen, Y., & Chiang, N. (2023). Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics, 41(3), 307. https://doi.org/10.1007/s40273-022-01227-6

Chicago Style (17th ed.) Citation

Chueh, Chen-Han, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, and Nai-Jung Chiang. "Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy." PharmacoEconomics 41, no. 3 (2023): 307. https://doi.org/10.1007/s40273-022-01227-6.

MLA (9th ed.) Citation

Chueh, Chen-Han, et al. "Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy." PharmacoEconomics, vol. 41, no. 3, 2023, p. 307, https://doi.org/10.1007/s40273-022-01227-6.